

New trial evidence and guidelines on heart failure: news from the European Society of Cardiology Congress 2021.

Eur Heart J Cardiovasc Pharmacother. 2021;7:e89-e90. PMID: 34529057
<https://pubmed.ncbi.nlm.nih.gov/34529057/>

11. Savarese G*, Stolfo D*, Sinagra G, Lund LH.
Heart failure with mid-range or mildly reduced ejection fraction.
Nat Rev Cardiol. 2022;19:100-116. PMID: 34489589 *Equal contribution
<https://pubmed.ncbi.nlm.nih.gov/34489589/>
12. Magavern EF, Kaski JC, Turner RM, Drexel H, Janmohamed A, Scourfield A, Burrage D, Floyd CN, Adeyeye E, Tamargo J, Lewis BS, Kjeldsen KP, Niessner A, Wassmann S, Sulzgruber P, Borry P, Agewall S, Semb AG, Savarese G, Pirmohamed M, Caulfield MJ.
Challenges in cardiovascular pharmacogenomics implementation: a viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy.
Eur Heart J Cardiovasc Pharmacother. 2022;8:100-103. PMID: 34463331
<https://pubmed.ncbi.nlm.nih.gov/34463331/>
13. Becher PM, Savarese G.
PharmaPulse: new trial evidence from the HFA/ESC Heart Failure Congress 2021.
Eur Heart J Cardiovasc Pharmacother. 2021;7:e88. PMID: 34415014
<https://pubmed.ncbi.nlm.nih.gov/34415014/>
14. Savarese G, Butler J, Lund LH, Bhatt DL, Anker SD.
Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms.
Cardiovasc Res. 2021 Aug 13;cvab271. doi: 10.1093/cvr/cvab271. Online ahead of print. PMID: 34390570
<https://pubmed.ncbi.nlm.nih.gov/34390570/>
15. Savarese G, Merlo M, Coats AJS, Metra M.
Best of European Journal of Heart Failure at the ESC/HFA Heart Failure Congress 2021.
Eur J Heart Fail. 2021;23:1424-1427. PMID: 34263508
<https://pubmed.ncbi.nlm.nih.gov/34263508/>
16. Herrington WG*, Savarese G*, Haynes R, Marx N, Mellbin L, Lund LH, Dendale P, Seferovic P, Rosano G, Staplin N, Baigent C, Cosentino F.
Cardiac, renal, and metabolic effects of sodium-glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium-glucose co-transporter 2 inhibitors.
Eur J Heart Fail. 2021;23:1260-1275. PMID: 34184823. *Equal contribution
<https://pubmed.ncbi.nlm.nih.gov/34184823/>
17. Drexel H, Pocock SJ, Lewis BS, Saely CH, Kaski JC, Rosano GMC, Tautermann G, Huber K, Dopheide JF, Mader A, Niessner A, Savarese G, Schmidt TA, Semb AG, Tamargo J, Wassmann S, Clodi M, Kjeldsen KP, Agewall S.

**Subgroup analyses in randomized clinical trials: value and limitations.
Review #3 on important aspects of randomized clinical trials in
cardiovascular pharmacotherapy.**

Eur Heart J Cardiovasc Pharmacother. 2022;8:302-310. PMID: 34180504
<https://pubmed.ncbi.nlm.nih.gov/34180504/>

18. Stolfo D, Savarese G.
Association between heart failure and cancer: is gender the answer?
Eur J Heart Fail. 2021;23:1722-1724. PMID: 34114282
<https://pubmed.ncbi.nlm.nih.gov/34114282/>
19. Sinagra G, Pagura L, Stolfo D, Fabris E, Savarese G, Rapezzi C, Ferrari R, Merlo M.
Combining New Classes of Drugs for HFrEF: from Trials to Clinical Practice.
Eur J Intern Med. 2021;90:10-15. PMID: 34090751
<https://pubmed.ncbi.nlm.nih.gov/34090751/>
20. Kapelios CJ, Canepa M, Savarese G, Lund LH.
Use of loop diuretics in chronic heart failure: do we adhere to the Hippocratic principle "do no harm"?
Eur J Heart Fail. 2021 May 16. doi: 10.1002/ejhf.2218. Online ahead of print. PMID: 33998132
<https://pubmed.ncbi.nlm.nih.gov/33998132/>
21. Kapelios CJ, Canepa M, Savarese G, Lund LH.
Use of loop diuretics in chronic heart failure: do we adhere to the Hippocratic principle 'do no harm'?
Eur J Heart Fail. 2021 Jul;23(7):1068-1075. doi: 10.1002/ejhf.2214. Epub 2021 May 21. PMID: 33963796
<https://pubmed.ncbi.nlm.nih.gov/33963796/>
22. Krogager ML, Kragholm K, Thomassen JQ, Søgaard P, Lewis BS, Wassmann S, Baumgartner I, Ceconi C, Schmidt TA, Kaski JC, Drexel H, Semb AG, Agewall S, Niessner A, Savarese G, Kjeldsen KP, Borghi C, Tamargo J, Torp-Pedersen C.
Update on management of hypokalaemia and goals for the lower potassium level in patients with cardiovascular disease: a review in collaboration with the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy.
Eur Heart J Cardiovasc Pharmacother. 2021;7:557-567. PMID: 33956964
<https://pubmed.ncbi.nlm.nih.gov/33956964/>
23. Rao VN, Fudim M, Savarese G, Butler J.
Polypharmacy in Heart Failure with Reduced Ejection Fraction: Progress, Not Problem.
Am J Med. 2021;134:1068-1070. PMID: 33939999
<https://pubmed.ncbi.nlm.nih.gov/33939999/>
24. Rosano GMC, Moura B, Metra M, Böhm M, Bauersachs J, Ben Gal T, Adamopoulos S, Abdelhamid M, Bistola V, Čelutkienė J, Chioncel O, Farmakis

D, Ferrari R, Filippatos G, Hill L, Jankowska EA, Jaarsma T, Jhund P, Lainscak M, Lopatin Y, Lund LH, Milicic D, Mullens W, Pinto F, Ponikowski P, **Savarese G**, Thum T, Volterrani M, Anker SD, Seferovic PM, Coats AJS.

Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology.

Eur J Heart Fail. 2021;23:872-881. PMID: 33932268

<https://pubmed.ncbi.nlm.nih.gov/33932268/>

25. Ferrannini G, **Savarese G**, Rydén L.

Sodium-glucose transporter inhibition in heart failure: from an unexpected side effect to a novel treatment possibility.

Diabetes Res Clin Pract. 2021;175:108796. PMID: 33845051

<https://pubmed.ncbi.nlm.nih.gov/33845051/>

26. Magavern EF, Kaski JC, Turner RM, Drexel H, Janmohamed A, Scourfield A, Burrage D, Floyd CN, Adeyeye E, Tamargo J, Lewis BS, Kjeldsen KP, Niessner A, Wassmann S, Sulzgruber P, Borry P, Agewall S, Semb AG, **Savarese G**, Pirmohamed M, Caulfield MJ.

The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy.

Eur Heart J Cardiovasc Pharmacother. 2022;8:85-99. PMID: 33638977

<https://pubmed.ncbi.nlm.nih.gov/33638977/>

27. Rosano GMC, Vitale C, **Savarese G**.

Sodium-glucose co-transporter 2 inhibitors in heart failure.

Eur Heart J Cardiovasc Pharmacother. 2021;7:e9-e10. PMID: 33576409

<https://pubmed.ncbi.nlm.nih.gov/33576409/>

28. **Savarese G**.

New evidence from the scientific sessions 2020 of the American Heart Association.

Eur Heart J Cardiovasc Pharmacother. 2021;7:e1. PMID: 33367726

<https://pubmed.ncbi.nlm.nih.gov/33367726/>

29. Drexel H, Lewis BS, Rosano GMC, Saely CH, Tautermann G, Huber K, Dopheide JF, Kaski JC, Mader A, Niessner A, **Savarese G**, Schmidt TA, Semb A, Tamargo J, Wassmann S, Per Kjeldsen K, Agewall S, Pocock SJ.

The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid, diabetes, and antithrombotic trials.

Eur Heart J Cardiovasc Pharmacother. 2021;7:453-459. PMID: 33135079

<https://pubmed.ncbi.nlm.nih.gov/33135079/>

30. Saraiva FA, Cerqueira RJ, **Savarese G**, Leite-Moreira AF.

The tight tie of MAG versus SAG in CABG.

Int J Cardiol. 2021;323:26. PMID: 33038409

<https://pubmed.ncbi.nlm.nih.gov/33038409/>

31. **Savarese G**.

Latest news on heart failure and atrial fibrillation from the European Society Of Cardiology Congress 2020.

Eur Heart J Cardiovasc Pharmacother. 2020;6:343-344. PMID: 33002119
<https://pubmed.ncbi.nlm.nih.gov/33002119/>

32. El Hadidi S, Rosano G, Tamargo J, Agewall S, Drexel H, Kaski JC, Niessner A, Lewis BS, Coats AJS, **Savarese G.**

Potentially inappropriate prescriptions in heart failure with reduced ejection fraction: ESC position statement on heart failure with reduced ejection fraction-specific inappropriate prescribing.

Eur Heart J Cardiovasc Pharmacother. 2022;8:187-210. PMID: 32941594
<https://pubmed.ncbi.nlm.nih.gov/32941594/>

33. **Savarese G**, Schrage B, Cosentino F, Lund LH, Rosano GMC, Seferovic P, Butler J.

Non-insulin antihyperglycaemic drugs and heart failure: an overview of current evidence from randomized controlled trials.

ESC Heart Fail. 2020;7:3438-51. PMID: 32909376
<https://pubmed.ncbi.nlm.nih.gov/32909376/>

34. **Savarese G**, Cosentino F.

The interaction between dapagliflozin and blood pressure in heart failure: new evidence dissipating concerns.

Eur Heart J. 2020;41:3419-3420. PMID: 32901257
<https://pubmed.ncbi.nlm.nih.gov/32901257/>

35. D'Amario D, Camilli M, Migliaro S, Canonico F, Galli M, Arcudi A, Montone RA, Borovac JA, Crea F, **Savarese G.**

Sex-Related Differences in Dilated Cardiomyopathy with a Focus on Cardiac Dysfunction in Oncology.

Curr Cardiol Rep. 2020;22:102. PMID: 32770480
<https://pubmed.ncbi.nlm.nih.gov/32770480/>

36. Kaski JC, Tamargo J, **Savarese G.**

Cardiovascular pharmacotherapy in older people: challenges posed by cardiovascular drug prescription in the elderly.

Eur Heart J Cardiovasc Pharmacother. 2020;6:277-279. PMID: 32687147
<https://pubmed.ncbi.nlm.nih.gov/32687147/>

37. **Savarese G.**

All about clinical trial course: one of the masterpieces of the European Society of Cardiology-Working Group on Cardiovascular Pharmacotherapy educational programme.

Eur Heart J Cardiovasc Pharmacother. 2020;6:275-276. PMID: 32584980
<https://pubmed.ncbi.nlm.nih.gov/32584980/>

38. Rosano G, **Savarese G.**

Inter-twinning Relationship Between Heart Failure and Atrial Fibrillation

Heart. 2020;106:1125-1126. PMID: 32482671
<https://pubmed.ncbi.nlm.nih.gov/32482671/>

39. Stolfo D, Savarese G
Sex-related differences in therapeutic response to mineralocorticoid receptor antagonists in heart failure: summarizing trial evidence
Eur J Heart Fail. 2020;22:845-847. PMID: 32103601
<https://www.ncbi.nlm.nih.gov/pubmed/32103601>

40. Schrage B, Linde C, Braunshweig F, Savarese G
Reply to the letter by Dr. Littmann
Circulation 2020;141:e648-e649. PMID: 32176544
<https://www.ncbi.nlm.nih.gov/pubmed/32176544>

41. Savarese G.
Behavioural Interventions to Reduce Cardiovascular Risk: Where Do We Stand?
Eur Cardiol 2019;14:139-140. PMID: 31933680
<https://www.ncbi.nlm.nih.gov/pubmed/31933680>

42. Lund LH, Savarese G.
PARAGON-HF - considerations for potential use of sacubitril-valsartan in real-world heart failure with mildly reduced ejection fraction.
J Card Fail 2019;25:1012-1013. PMID: 31818392
<https://www.ncbi.nlm.nih.gov/pubmed/31818392>

43. Lund LH, Savarese G, Dahlström U.
Iron deficiency in heart failure.
Int J Cardiol 2020;299:207. PMID: 31791539
<https://www.ncbi.nlm.nih.gov/pubmed/31791539>

44. Sulzgruber P, Wassmann S, Semb AG, Doehner W, Widimsky P, Gremmel T, Kaski JC, Savarese G, Rosano GMC, Borghi C, Kjeldsen K, Torp-Pedersen C, Schmidt TA, Lewis BS, Drexel H, Tamargo J, Atar D, Agewall S, Niessner A.
Oral Anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1.
Eur Heart J 2019;40:3010-3012. PMID: 31541549
<https://www.ncbi.nlm.nih.gov/pubmed/31541549>

45. Hollan I, Ronda N, Dessein P, Agewall S, Karpouzas G, Tamargo J, Niessner A, Savarese G, Rosano G, Kaski JC, Wassmann S, Meroni PL.
Lipid management in rheumatoid arthritis: a position paper by the Cardiovascular Pharmacotherapy Working Group of European Society of Cardiology.
Eur Heart J Cardiovasc Pharmacother 2020;6:104-114. PMID: 31397840
<https://www.ncbi.nlm.nih.gov/pubmed/31397840>

46. Drexel H, Rosano GMC, Lewis BS, Huber K, Vonbank A, Dopheide JF, Mader A, Niessner A, Savarese G, Wassmann S, Agewall S.
The age of RCT's 3 Important Aspects of RCT's in Cardiovascular Pharmacotherapy with examples from Lipid and Diabetes Trials.
Eur Heart J Cardiovasc Pharmacother 2020;6:97-103. PMID: 31298686
<https://www.ncbi.nlm.nih.gov/pubmed/31298686>

47. Stolfo D, Savarese G.
Use of Renin-Angiotensin-Aldosterone System Inhibitors in Older Patients with Heart Failure and Reduced Ejection Fraction.
Card Fail Rev 2019;5:70-73. PMID: 31179014
<https://www.ncbi.nlm.nih.gov/pubmed/31179014>
48. Savarese G, Lund LH, Carrero JJ.
Reply: Clinical Context of Dyskalemias Across the Heart Failure Spectrum and Their Associated Adverse Outcomes.
JACC Heart Fail 2019;7:533-534. PMID: 31146879
<https://www.ncbi.nlm.nih.gov/pubmed/31146879>
49. Sulzgruber P, Wassmann S, Semb AG, Doehner W, Widimsky P, Gremmel T, Kaski JC, Savarese G, Rosano GMC, Borghi C, Kjeldsen K, Torp-Pedersen C, Schmidt TA, Lewis BS, Drexel H, Tamargo J, Atar D, Agewall S, Niessner A.
Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke.
Eur Heart J Cardiovasc Pharmacother 2019;5:171-180. PMID: 31119266
<https://www.ncbi.nlm.nih.gov/pubmed/31119266>
50. Uijl A, Lund LH, Savarese G.
The GUIDE-IT heart failure risk prediction model: another fish in the sea?
Eur J Heart Fail 2019;21:779-780. PMID: 30983078
<https://www.ncbi.nlm.nih.gov/pubmed/30983078>
51. Cooper LB, Savarese G, Carrero JJ, Szabo B, Jernberg T, Jonsson A, Dahlbom C, Dahlstrom U, Larson A, Lund LH.
Clinical and research implications of serum versus plasma potassium measurements.
Eur J Heart Fail 2019;21:536-537. PMID: 30485595
<https://www.ncbi.nlm.nih.gov/pubmed/30485595>
52. Galli M, Andreotti F, Savarese G, D'Amario D, Vergallo R, Della Bona R, Caló L, Porto I, Crea F
Dropping aspirin in patients with atrial fibrillation undergoing percutaneous coronary intervention: a jump with a weak parachute?
Eur Heart J Cardiovasc Pharmacother 2019;5:55-56. PMID: 30289484
<https://www.ncbi.nlm.nih.gov/pubmed/30289484>
53. Vonbank A, Drexel H, Agewall S, Lewis BS, Dopheide JF, Kjeldsen K, Ceconi C, Savarese G, Rosano G, Wassmann S, Niessner A, Schmidt TA, Saely CH, Baumgartner I, Tamargo J.
Reasons for disparity in statin adherence rates between clinical trials and real-world observations: a review.
Eur Heart J Cardiovasc Pharmacother 2018;4:230-236. PMID: 30099530
<https://www.ncbi.nlm.nih.gov/pubmed/30099530>
54. Savarese G, Vasko P, Jonsson Å, Edner M, Dahlström U, Lund LH.

The Swedish Heart Failure Registry: a living, ongoing quality assurance and research in heart failure.

Ups J Med Sci 2019;124:65-69. PMID: 30092697
<https://www.ncbi.nlm.nih.gov/pubmed/30092697>

55. Savarese G, D'Amario D.

Sex Differences in Heart Failure.

Adv Exp Med Biol. 2018;1065:529-544. PMID: 30051405
<https://www.ncbi.nlm.nih.gov/pubmed/30051405>

56. Rosano GMC, Tamargo J, Kjeldsen KP, Lainscak M, Agewall S, Anker SD, Ceconi C, Coats AJS, Drexel H, Filippatos G, Kaski JC, Lund L, Niessner A, Savarese G, Schmidt TA, Seferovic P, Wassmann S, Walther T, Lewis BS.

Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with RAAS-inhibitors - Coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology.

Eur Heart J Cardiovasc Pharmacother 2018;4:180-188. PMID: 29726985
<https://www.ncbi.nlm.nih.gov/pubmed/29726985>

57. Lund LH, Vedin O, Savarese G.

Is ejection fraction in heart failure a limitation or an opportunity?

Eur J Heart Fail. 2018;20:431-432. PMID: 29333631
<https://www.ncbi.nlm.nih.gov/pubmed/29333631>

58. Niessner A, Tamargo J, Koller L, Saely CH, Schmidt TA, Savarese G, Wassmann S, Rosano G, Ceconi C, Torp-Pedersen C, Kaski JC, Kjeldsen KP, Agewall S, Walther T, Drexel H, Lewis BS.

Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy.

Eur Heart J 2018;39:2274-2281. PMID: 29126266
<https://www.ncbi.nlm.nih.gov/pubmed/29126266>

59. Savarese G, Lund LH.

Ticagrelor versus prasugrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: An unresolved issue.

Int J Cardiol 2017;249:77-78. PMID: 29121762
<https://www.ncbi.nlm.nih.gov/pubmed/29121762>

60. Savarese G, Lund LH.

Up-titrating angiotensin-converting enzyme inhibitors in heart failure: evidence and challenges.

Eur J Heart Fail 2018;20:370-372. PMID: 28980436
<https://www.ncbi.nlm.nih.gov/pubmed/28980436>

61. Savarese G, Lund LH.

Global Public Health Burden of Heart Failure.

Card Fail Rev 2017;3:7-11. PMID: 28785469
<https://www.ncbi.nlm.nih.gov/pubmed/28785469>

62. Prastaro M, Pirozzi E, Gaibazzi N, Paolillo S, Santoro C, **Savarese G**, Losi MA, Esposito G, Perrone Filardi P, Trimarco B, Galderisi M.
Expert Review on the Prognostic Role of Echocardiography after Acute Myocardial Infarction.
J Am Soc Echocardiogr 2017;30:431-443.e2. PMID: 28477781
<https://www.ncbi.nlm.nih.gov/pubmed/28477781>
63. Tamargo J, Rosano G, Thomas W, Duarte J, Niessner A, Kaski JC, Cecconi C, Drexel H, Kjeldsen K, **Savarese G**, Torp-Pedersen C, Atar D, Lewis BS, Agewall S.
Gender differences in the effects of cardiovascular drugs.
Eur Heart J Cardiovasc Pharmacother 2017;3:163-182. PMID: 28329228
<https://www.ncbi.nlm.nih.gov/pubmed/28329228>
64. **Savarese G**, Lund LH.
Digoxin: Beneficial or Harmful?
Eur Heart J Cardiovasc Pharmacother 2017;3:127-128. PMID: 28206589
<https://www.ncbi.nlm.nih.gov/pubmed/28206589>
65. **Savarese G**, Lund LH, Rosano GM.
Incretin-based therapy for type 2 diabetes: A real class effect?
Int J Cardiol 2016;227:141-142. PMID: 27866064
<https://www.ncbi.nlm.nih.gov/pubmed/27866064>
66. **Savarese G**, Perrone-Filardi P.
Reply to: Ezetimibe: A real effect?
Int J Cardiol 2016;209:337-8. PMID: 26874996
<https://www.ncbi.nlm.nih.gov/pubmed/26874996>
67. Camici GG, **Savarese G**, Akhmedov A, Lüscher TF.
Molecular mechanism of endothelial and vascular aging: implications for cardiovascular disease.
Eur Heart J 2015;36:3392-403. PMID: 26543043
<https://www.ncbi.nlm.nih.gov/pubmed/26543043>
68. Perrone-Filardi P, Paolillo S, Costanzo P, **Savarese G**, Trimarco B, Bonow RO.
The role of metabolic syndrome in heart failure.
Eur Heart J 2015;36:2630-4. PMID: 26242711
<https://www.ncbi.nlm.nih.gov/pubmed/26242711>
69. **Savarese G**.
Vitamin D and parathyroid hormone: a new piece in the puzzle of cardiovascular risk.
J Cardiovasc Med (Hagerstown) 2015;16:71. PMID: 25427049
<https://www.ncbi.nlm.nih.gov/pubmed/25427049>
70. Prastaro M, D'Amore C, Paolillo S, Losi M, Marciano C, Perrino C, Ruggiero D, Gargiulo P, **Savarese G**, Trimarco B, Perrone Filardi P.
Prognostic role of transthoracic echocardiography in patients affected by heart failure and reduced ejection fraction.
Heart Fail Rev 2015;20:305-16. PMID: 25355298

<https://www.ncbi.nlm.nih.gov/pubmed/25355298>

71. Gargiulo P, Cuocolo A, Dellegrottaglie S, Prastaro M, **Savarese G**, Assante R, Zampella E, Paolillo S, Scala O, Ruggiero D, Marsico F, Perrone Filardi P.
Nuclear Assessment of Right Ventricle.
Echocardiography 2015;32 Suppl 1:S69-74. PMID: 25238036
<https://www.ncbi.nlm.nih.gov/pubmed/25238036>
72. **Savarese G**, Perrone-Filardi P.
Reply to Letter to the Editor: "Benefits of Statins in Elderly Subjects Without Established Cardiovascular Disease"
J Am Coll Cardiol 2014;63:2303. PMID: 24727257
<https://www.ncbi.nlm.nih.gov/pubmed/24727257>
73. Dellegrottaglie S, Guarini P, **Savarese G**, Gambardella F, Iudice FL, Cirillo A, Vitagliano A, Formisano T, Pellegrino AM, Bossone E, Perrone-Filardi P.
Cardiac magnetic resonance for the assessment of myocardial viability: from pathophysiology to clinical practice.
J Cardiovasc Med (Hagerstown) 2013;14:862-9. PMID: 23756415
<https://www.ncbi.nlm.nih.gov/pubmed/23756415>
74. Bossone E, **Savarese G**, Ferrara F, Citro R, Mosca S, Musella F, Limongelli G, Manfredini R, Cittadini A, Perrone-Filardi P
Takotsubo cardiomyopathy: overview
Heart Fail Clin 2013;9:249-66. PMID: 23562126
<https://www.ncbi.nlm.nih.gov/pubmed/23562126>
75. Perrone-Filardi P, Musella F, **Savarese G**, Cecere M, Marciano C, Scala O, MD1, Rengo G, Dellegrottaglie S, Cuocolo A, Leosco D.
Coronary computed tomography: current role and future perspectives for cardiovascular risk stratification.
Eur Heart J Cardiovasc Imaging 2012;13:453-8. PMID: 22523008
<https://www.ncbi.nlm.nih.gov/pubmed/22523008>
76. Perrone-Filardi P, **Savarese G**, Rengo G, Mattiello G, Leosco D.
Viability and left ventricular dysfunction: what changes after STICH?
G Ital Cardiol 2012;13:81-3. PMID: 22322546
<https://www.ncbi.nlm.nih.gov/pubmed/22322546>
77. **Savarese G**, Losco T, Parente A, Musella F, Pirozzi E, Mosca S, Casaretti L, Formisano R, Conte S, Bologna A, Mattiello G, Perrone-Filardi P.
Clinical applications of MIBG SPECT in chronic heart failure
G Ital Cardiol 2012;13:91-7. PMID: 22322548
<https://www.ncbi.nlm.nih.gov/pubmed/22322548>
78. Perrone-Filardi P, Paolillo S, Dellegrottaglie S, Gargiulo P, **Savarese G**, Marciano C, Casaretti L, Cecere M, Musella F, Pirozzi E, Parente A, Cuocolo A.
Assessment of cardiac sympathetic activity by MIBG imaging in patients with heart failure: a clinical appraisal.
Heart 2011;97:1828-33. PMID: 21917663
<https://www.ncbi.nlm.nih.gov/pubmed/21917663>

79. Perrone-Filardi P, Costanzo P, Dellegrottaglie S, Gargiulo P, Ruggiero D, **Savarese G**, Parente A, D'Amore C, Cuocolo A, Chiariello M.
Prognostic role of myocardial single photon emission computed tomography in the elderly
Journal of Nuclear Cardiology 2010;17:310-5. PMID: 20033857
<https://www.ncbi.nlm.nih.gov/pubmed/20033857>
80. Monda C, Scala O, Paolillo S, **Savarese G**, Cecere M, D'Amore C, Parente A, Musella F, Mosca S, Filardi PP.
Sleep apnea and heart failure: pathophysiology, diagnosis and therapy.
G Ital Cardiol 2010;11:815-22. PMID: 21348318
<https://www.ncbi.nlm.nih.gov/pubmed/21348318>
81. Filardi PP, Cecere M, **Savarese G**, Damore C, Parente A, Conte S, Coutsoumbas G.
Inflammation and lipids in the coronary pathology. Risk factors, causes or therapeutic target?
G Ital Cardiol 2010;11(12 Suppl 3):10S-15S. PMID: 21491734
<https://www.ncbi.nlm.nih.gov/pubmed/21491734>

3 INTERNATIONAL SCIENTIFIC CONGRESSES

3.1 Invited speaker or chair

1. **HFA clinical trial course in a nutshell (chairman)**
Heart Failure & World Congress on Acute Heart Failure 2022. Madrid, 21-24 May 2022
2. **Diagnosis and monitoring (chairman)**
Heart Failure & World Congress on Acute Heart Failure 2022. Madrid, 21-24 May 2022
3. **Registries for implementation of evidence-based treatments (speaker)**
Heart Failure & World Congress on Acute Heart Failure 2022. Madrid, 21-24 May 2022
4. **The year's best papers on heart failure: Epidemiology (speaker)**
Heart Failure & World Congress on Acute Heart Failure 2022. Madrid, 21-24 May 2022
5. **Stroke treatment in heart failure (speaker)**
Heart Failure & World Congress on Acute Heart Failure 2022. Madrid, 21-24 May 2022
6. **The conundrum of comorbidities and their role in management (speaker)**
Heart Failure & World Congress on Acute Heart Failure 2022. Madrid, 21-24 May 2022
7. **Implementing use of heart failure treatments in clinical practice (chairman)**

Heart Failure & World Congress on Acute Heart Failure 2022. Madrid, 21-24 May 2022

8. **Optimizing foundational therapies in clinical practice. The patient with HFpEF (speaker)**
Heart Failure & World Congress on Acute Heart Failure 2022. Madrid, 21-24 May 2022
9. **The Socio Economic Impact of Non-communicable diseases: Global Perspectives (speaker)**
International cardio-metabolic forum 2022. Zurich, 14 May 2022
10. **Heart failure with mildly reduced ejection fraction: definition, epidemiology and treatment (speaker)**
Advances in heart failure, cardiomyopathies and pericardial disease. Trieste (Italy), 22-23 April 2022
11. **Low frequency of iron deficiency testing – are there any misconceptions and what does real world data tell us? (speaker)**
Kardiovaskulära Vårmetet 2022. Malmö, 7 April 2022
12. **Definition and classification of heart failure (organizer of the event and speaker)**
Masterclasses in the centers of expertise. Online, 17-18 March 2022
13. **HFpEF (organizer of the event and chairman)**
Masterclasses in the centers of expertise. Online, 17-18 March 2022
14. **Pharmacological treatments in HFmrEF (organizer of the event and speaker)**
Masterclasses in the centers of expertise. Online, 17-18 March 2022
15. **HFrEF devices and organizational aspects (organizer of the event and chairman)**
Masterclasses in the centers of expertise. Online, 17-18 March 2022
16. **SGLT2 inhibition in clinical practice. Improving QoL and Symptoms e-SPACE CRM. Online, 4-6 March 2022**
17. **Gender differences in cardiac care and outcome (speaker)**
Cardiovascular Pharmacotherapy in Women – European Society of Cardiology, Working group on Cardiovascular Pharmacotherapy. Online, 17 February 2022
18. **Registries to support implementation of care and trial design in heart failure (speaker)**
Heart Failure Association of the European Society of Cardiology webinar. Online, 15 February 2022
19. **The many faces of HFpEF – not just one disease (speaker)**
D-HF 2022. Frankfurt 9-10 December 2021

20. **ARNI och andra nya läkemedelsalternativ (speaker)**
Hjärtsvikt. Malmö, 17-18 November 2021
21. **Kidney disease and heart failure (speaker)**
e-SPACE HF. Online, 8-10 October 2021
22. **State of the art for the management of chronic HF (chairman)**
e-SPACE HF. Online, 8-10 October 2021
23. **Antiarrhythmics (chairman)**
Pharmacotherapy in Older People – European Society of Cardiology, Working group on Cardiovascular Pharmacotherapy. Online, 14 October 2021
24. **Optimization of heart failure treatments (speaker)**
Heart Failure Summit. Cairo, 23-24 September 2021.
25. **Kidney disease and heart failure (speaker)**
Heart Failure – Recent updates and new guidelines. Dubai, 10-11 September 2021
26. **Treatment approaches in HFpEF (speaker)**
Heart Failure – Recent updates and new guidelines. Dubai, 10-11 September 2021
27. **Best paper of the European Journal of Heart Failure (speaker)**
Heart Failure Association of the European Society of Cardiology Online Congress. 29 June – 1 July 2021
28. **When to use new oral anticoagulants in patients with heart failure (speaker)**
Heart Failure Association of the European Society of Cardiology Online Congress. 29 June – 1 July 2021
29. **Optimal medical therapy in the real world: clinical and administrative registries (speaker)**
Heart Failure Association of the European Society of Cardiology Online Congress. 29 June – 1 July 2021
30. **HFrEF treatment: not to easy as it seems (chairman)**
Heart Failure Association of the European Society of Cardiology Online Congress. 29 June – 1 July 2021
31. **Five things to know about diagnosis of HFpEF (speaker)**
Canadian Heart Failure Society's (CHFS) annual HF Update 2021 Virtual. Online. 7-8 May 2021.
32. **Observational studies and registries (speaker)**
EuroCVP 2021 by Working Group on Cardiovascular Pharmacology of European Society of Cardiology. Online, 11 June 2021
33. **Clinical trial categories, statistical issues and interpretation (chairman)**

EuroCVP 2021 by Working Group on Cardiovascular Pharmacology of European Society of Cardiology. Online, 11 June 2021

34. **Tips in statistical analysis (speaker)**
Center of excellence masterclass. Online, 21 January 2021
35. **Latest evidence in ICD therapy and new technologies in AF ablation (speaker)**
Rhythm Intervention Online 2020. Online, 11 December 2020
36. **LDL reduction for the prevention of cardiovascular disease (speaker)**
51st Annual Congress of the Italian Association of Clinical Cardiologists (ANMCO). Rimini (Italy) 27-29 August 2020
37. **Hyper- and Hypokalemias in heart failure: epidemiology and causes (speaker)**
Heart Failure Association of the European Society of Cardiology webinar. Online, 19 March 2020
38. **Are devices still relevant in contemporary clinical setting (speaker)**
Global Grand Rounds. Minneapolis (US), 5 February 2020
39. **Antiarrhythmics (chairman)**
Pharmacotherapy in Older People – European Society of Cardiology, Working group on Cardiovascular Pharmacotherapy. London, 25 October 2019
40. **A case of a patient with chronic kidney disease and hyperkalemia: how to optimise RAAS inhibitors? (speaker)**
Heart Failure 2019 and World congress on acute heart failure (HFA). Athens, 25-28 May 2019.
41. **Management of peripheral arterial disease (speaker)**
The Year in Cardiology. Dubai, 22-24 February 2019
42. **Update on the ESC guidelines on arterial hypertension (speaker)**
The Year in Cardiology. Dubai, 22-24 February 2019
43. **RAS and natriuretic peptides role in heart failure (speaker)**
“Napoli Cuore” Congress. Naples, 23 March 2018
44. **Unmet needs in heart failure in 2018 (speaker)**
Cardiovascular Pharmacotherapy: from the population to the individual. Moscow, 21 April 2018
45. **Heart Failure (chairman)**
Cardiovascular Pharmacotherapy: from the population to the individual. Moscow, 21 April 2018
46. **Heart failure with recovered EF (speaker)**
Heart failure 2030: cutting the edge of the failing heart
Pisa, 23-24 April 2018

47. **Cardiovascular pharmacologists and trialists of tomorrow (chairman)**
EuroCVP 2018 by Working Group on Cardiovascular Pharmacology of European Society of Cardiology. Tel Aviv, 13-14 May 2018
48. **Potential of real-world data analysis (speaker)**
proCardio2018. Madrid, 29-30 October 2018
49. **Interpreting Meta-Analyses and Clinical Trials: Can we Believe the Data? (speaker)**
ICCAD 2017 – Innovations in coronary artery disease. Venice, 15-17 October 2017
50. **Clinical trial design and statistical methods (speaker)**
ESC Congress 2017. Barcelona, 26-30 August 2017
51. **Cardiovascular risk in diabetics (speaker)**
EuroCVP 2017 by Working Group on Cardiovascular Pharmacology of European Society of Cardiology. Rome, 26-28 May 2017
52. **Cardiovascular pharmacologists and trialists of tomorrow (chairman)**
EuroCVP 2017 by Working Group on Cardiovascular Pharmacology of European Society of Cardiology. Rome, 26-28 May 2017

3.2 Oral presentations of own accepted abstracts

1. **Dapagliflozin utilization following hospitalization for heart failure: real-world insights from EVOLUTION HF, a multinational, observational study**
European Society of Cardiology Congress 2022. Barcelona, 26 – 29 August 2022
2. **EVOLUTION HF - Use of GDMTs in clinical practice**
Heart Failure & World Congress on Acute Heart Failure 2022. Madrid, 21-24 May 2022
Heart Failure Association of the European Society of Cardiology Online Congress. 29 June – 1 July 2021
3. **Heart Failure Drug Titration, Discontinuation and Mortality and HF Hospitalization Risk: A Multinational Observational Study (US, UK and Sweden)**
Heart Failure Association of the European Society of Cardiology Online Congress. 29 June – 1 July 2021
4. **Eligibility for dapagliflozin and empagliflozin in real-world heart failure based on DAPA-HF, DELIVER, EMPEROR-Reduced and EMPEROR-Preserved selection criteria**
Heart Failure Association of the European Society of Cardiology Online Congress. 29 June – 1 July 2021

5. **How many real world HFpEF patients would be suitable for sacubitril/valsartan treatment according to the PARAGON-HF trial**
Late breaking trial session. Heart failure 2020 and World congress on acute heart failure (HFA) held online as HFA Discoveries in June 2020
6. **Association between beta-blocker use and mortality/morbidity in elderly patients with heart failure with reduced ejection fraction: a prospective score-matched cohort study**
Late breaking trial session. European Society of Cardiology Congress 2019. Paris, 31 August – 4 September 2019
7. **Empagliflozin is associated with a lower risk of post-acute heart failure re-hospitalization and mortality: insights from the EMPA-REG Outcome trial**
Highlight session on Heart Failure. American College of Cardiology.19, 68th Annual Scientific Session and Expo. New Orleans, 16-18 March 2019
8. **Optimizing patient selection in heart failure trials: the role of NT-proBNP**
European Society of Cardiology Congress 2018. Munich, 31 August – 4 September 2018
9. **Association between renin-angiotensin system inhibitor use and mortality/morbidity in elderly patients with heart failure with reduced ejection fraction: a prospective propensity score-matched cohort**
Late breaking trial session. Heart failure 2018 and World congress on acute heart failure (HFA). Vienna, 26-29 May 2018
10. **Incidence of dyskalemia in heart failure with preserved, mid-range, and reduced ejection fraction: an analysis of 6,401 patients from the swedish heart failure registry**
Young investigator award session. Heart failure 2018 and World congress on acute heart failure (HFA). Vienna, 26-29 May 2018
11. **Predictors of and outcomes associated with referral to a heart failure nurse-led clinic: an analysis of 40,992 patients from the Swedish Heart Failure Registry**
American College of Cardiology.18, 67th Annual Scientific Session and Expo. Orlando, 10-12 March 2018.
12. **Impact of CHA2DS2-VASc and HAS-BLED SCORES on oral anticoagulant use and outcomes in patients with atrial fibrillation and concomitant heart failure: an analysis of 22,055 patients from the SwedeHF (finalist Young Investigator Award on Population Science)**
European Society of Cardiology Congress 2017. Barcelona, 26-30 August 2017
13. **Patterns and prognostic role of N-terminal pro-B-type Natriuretic Peptide in heart failure with mid-range vs. preserved vs. reduced ejection fraction**
European Society of Cardiology Congress 2017. Barcelona, 26-30 August 2017

14. **Use of mineralocorticoid receptor antagonists in a real-world population with heart failure and reduced ejection fraction: an analysis of 24,529 patients from the Swedish heart failure registry**
Heart Failure and the World Congress on Acute Heart Failure (HFA). Paris, 29 April - 2 May 2017
15. **Oral anticoagulant use in patients with atrial fibrillation and concomitant heart failure: an analysis of 22,719 patients from the Swedish heart failure registry**
Heart Failure and the World Congress on Acute Heart Failure (HFA). Paris, 29 April - 2 May 2017
16. **Mortality and Morbidity in Patients With Heart Failure and Reduced Ejection Fraction Exposed to Digoxin: Comprehensive Data According to Atrial Fibrillation in 23,708 Patients From the Swedish Heart Failure Registry**
Highlight session on Heart Failure. American College of Cardiology.17, 66th Annual Scientific Session and Expo. Washington, 17-19 March 2017.
17. **Mortality and morbidity in heart failure patients exposed to Digoxin: comprehensive data according to ejection fraction and atrial fibrillation in 41881 patients from the Swedish Heart Failure Registry**
European Society of Cardiology Congress 2016. Rome, 27-31 August 2016.
18. **Efficacy and safety of dipeptidyl peptidase 4 inhibitors and sodium-glucose linked cotransporter-2 inhibitors in patients with type 2 diabetes mellitus: a meta-analysis**
European Society of Cardiology Congress 2016. Rome, 27-31 August 2016.
19. **Efficacy and safety of dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes mellitus: a meta-analysis of 116 trials.**
Heart Failure and the World Congress on Acute Heart Failure (HFA). Florence, 21-24 May 2016.
20. **Comparative associations between angiotensin converting enzyme inhibitors, angiotensin receptor blockers and their combination, and outcomes in patients with heart failure and reduced ejection fraction**
European Society of Cardiology Congress 2015, London, 29 August – 2 September 2015
21. **Novel oral anticoagulants in patients with atrial fibrillation and heart failure: a meta-analysis**
European Society of Cardiology Congress 2015, London, 29 August – 2 September 2015
22. **Efficacy and Safety of Novel Oral Anticoagulants in Patients with Atrial Fibrillation and Heart Failure: A Meta-Analysis of Phase III Clinical Trials.**
American College of Cardiology.15, 64th Annual Scientific Session and Expo. San Diego, 14-16 March 2015.

23. **Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients: A Meta-Analysis of 95 Trials.**
American Heart Association Scientific Session 2014. Chicago, 15-19 Nov 2014
24. **Prognostic impact of metabolic syndrome in patients with chronic heart failure: data from GISSI-HF trial**
European Society of Cardiology Congress 2014. Barcelona, 29 Aug – 2 Sep 2014
25. **Prognostic Impact of Metabolic Syndrome in Patients With Chronic Heart Failure: Data From Gissi-Hf Trial**
American Heart Association Scientific Session 2013. Dallas, 16 - 20 November 2013.
26. **Benefits of statins in elderly subjects without established cardiovascular disease. a meta-analysis.**
European Society of Cardiology Congress 2013. Amsterdam, 31 Aug – 4 Sep 2013.
27. **Changes of urinary albumin excretion and cardiovascular events: a meta-regression analysis of 32 randomized trials and 80,812 patients.**
European Society of Cardiology Congress 2013. Amsterdam, 31 Aug – 4 Sep 2013.
28. **Do Changes of Urinary Albumin Excretion Predict Cardiovascular Events? A Meta-regression Analysis of 32 Randomized Trials.**
American Heart Association Scientific Session 2012. Los Angeles, 3-7 November 2012.
29. **Effects of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Mortality and Cardiovascular Events in Patients Without Heart Failure. A Meta-Analysis of Randomized Clinical Trials in 108,233 patients.**
American Heart Association Scientific Session 2012. Los Angeles, 3-7 November 2012.
30. **Left Ventricular Hypertrophy Reduction and Clinical Events. A Meta-regression Analysis of 14 Studies in 12,809 Hypertensive Patients.**
American Heart Association Scientific Session 2012. Los Angeles, 3-7 November 2012.
31. **Effects of atorvastatin and rosuvastatin on renal function in patients at high cardiovascular risk: a meta-analysis of 21 randomized trials.**
European Society of Cardiology Congress 2012. Munich, 25-29 August 2012.

4 RESEARCH FUNDING OBTAINED IN THE PAST FIVE YEARS

4.1 External research funding obtained in international or national competition as *principal applicant*

1. EU Horizon. Call HORIZON-HLTH-2021-TOOL-06.
Project: A European Health Data Toolbox for Enhancing Cardiology Data Interoperability, Reusability and Privacy
Awarded 312.500 euros in January 2022 (funding for 4 years)
2. SIC (Italian Society of Cardiology).
Project: Phenotyping Heart failure with Preserved and Reduced Ejection Fraction: Data from the Swedish Heart Failure Registry
Awarded 25.000 euros. September 1st 2016 – August 31st 2017
3. ESC (European Society of Cardiology) Research Grant.
Title: P66Shc protein as a determinant of vascular hyperglycemic memory in patients with type 2 diabetes: a pilot study
Awarded 25.000 euros. July 2013 – 30 June 2014

4.2 External research funding obtained in international or national competition as *co-applicant*

1. Hjärt-Lungfonden “Projektbidrag”
Title: Biventrikulär pacemakerbehandling och annan devicebehandling vid hjärtsvikt
Awarded 3.300.000 SEK. 2021-2023
2. Italian Ministry of Education, Universities and Research
Title: Non-coding RNAs and myocardial fibrosis in patients with acute coronary syndrome: impact on left ventricular remodeling
Awarded 390.000 euros. April 2018 – April 2021
3. Hjärt-Lungfonden “Forskarmånader” for Gianluigi Savarese’s PhD salary (2017-8)
Title: Heart failure with preserved and mid-range ejection fraction - importance of proper characterization for future interventional trials.
Awarded 409.500 SEK. January – December 2018

4.3 Significant other research funding received (donation, grant in local competition – e.g. ALF project) as *principal applicant*

1. Investigator initiated project supported by AstraZeneca
Title: Use of the Inhibitors of sodium–glucose cotransporter 2 in patients with Heart Failure and Type 2 Diabetes Mellitus
Awarded 1.200.000 SEK. 2019-2020
2. Investigator initiated project supported by Vifor
Title: Real world evidence study to assess chronic heart failure patients with iron deficiency/anemia in terms of specific patterns of iron treatment and health care outcomes
Awarded 500.000 SEK. 2019-2020

3. Investigator initiated project supported by Novartis
Title: Eligibility for Sacubitril/Valsartan in real world HFpEF patients: data from the Swedish Heart Failure Registry and KaRen Study
Awarded 71.000 USD. 2019-2020
4. Investigator initiated project supported by Boston Scientific
Title: Contemporary effectiveness of cardiac resynchronization therapy and implantable cardioverter defibrillator in patients with heart failure with reduced ejection fraction: data from the Swedish Heart Failure Registry
Awarded 110.800 Euros. 2020-2021
5. Investigator initiated project supported by Pharmacosmos
Title: Phenotyping heart failure patients with iron deficiency (2020-2021)
Awarded 708.000 SEK. 2020-2022
6. Investigator initiated project supported by Boehringer Ingelheim
Title: Use of care in heart failure patients across the ejection fraction spectrum
Awarded 557.500 SEK. 2020-2022
7. Investigator initiated project supported by AstraZeneca
Title: Awareness of indications and current practice in use of heart failure treatments: A survey study
Awarded 500.000 SEK 2021-2022
8. Investigator initiated project supported by Bayer
Title: Eligibility for Vericiguat in real-world heart failure patients: data from the Swedish Heart Failure Registry (VICTORIA eligibility)
Awarded 67.500 Euros. 2021-2023
9. Investigator initiated project supported by MSD
Title: N-terminal pro-B-type natriuretic peptide (NT-proBNP) in patients with heart failure, with a focus on worsening heart failure, in Sweden.
Awarded 885.000 SEK. 2021-2023
10. Investigator initiated project supported by Novartis
Title: Implementation, timing and modalities of initiation/up-titration of ARNI in a Swedish real world heart failure population with reduced ejection fraction.
Awarded 850.000 SEK. 2022-2024
11. Investigator initiated project supported by Cytokinetics
Title: Eligibility for Omecamtiv Mecarbil in real world heart failure patients: Data from the Swedish Heart Failure Registry
Awarded 95.000 USD. 2022-2024 (legal agreement in preparation)

Investigator initiated grant supported by Edwards

Title: Epidemiology of tricuspid regurgitation.

Awarded 82.500 Euros. 2022-2024 (legal agreement in preparation)



4.4 Significant other research funding received (donation, grant in local competition – e.g. ALF project) as co-applicant

1. Investigator initiated project supported by Boehringer Ingelheim
Title: Epidemiology of heart failure (HF) by subtype (HFpEF, HFmrEF, HFfrEF) in patients with type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD), atrial fibrillation (AF), and in the general population (2017-2018)
Awarded 130.000 Euros. 2017-2020

5 SCIENTIFIC COLLABORATIONS

- **Heart Failure Association (HFA) of the European Society of Cardiology (ESC)**

The Applicant is currently board member of the HFA of the European Society of Cardiology (ESC). Given his expertise on registries and epidemiology, among others he is active member of the Committee on Surveys, Registries and Epidemiology. As such, he is heavily involved in 1) the ATLAS project, which is a unique compendium of data on the prevalence and incidence of heart failure, outcomes, health infrastructure and service provision across European countries; 2) he runs research projects in the Heart Failure Long-Term Registry II and contributed to the design of and will run research in the Heart Failure Registry III, which are among the most important registries in the field of heart failure worldwide.

The Applicant also actively contributes to the scientific production of the association, i.e. position documents and guidelines, and is currently leading a position document to tackle physicians' clinical inertia which is a cause of underuse of treatments in patients with heart failure. For this purpose, he has recently organized a workshop in London (March 2022) where all the European experts in heart failure have joined to contribute to this ambitious project.

[https://www.escardio.org/Sub-specialty-communities/Heart-Failure-Association-of-the-ESC-\(HFA\)/Research-and-Publications/hfa-atlas](https://www.escardio.org/Sub-specialty-communities/Heart-Failure-Association-of-the-ESC-(HFA)/Research-and-Publications/hfa-atlas)

[https://www.escardio.org/Sub-specialty-communities/Heart-Failure-Association-of-the-ESC-\(HFA\)/About/committees-and-study-groups](https://www.escardio.org/Sub-specialty-communities/Heart-Failure-Association-of-the-ESC-(HFA)/About/committees-and-study-groups)

1. Aimo A, Vergaro G, González A, Barison A, Lupón J, Delgado V, Richards AM, de Boer RA, Thum T, Arfsten H, Hülsmann M, Falcao-Pires I, Díez J, Foo RS, Chan MYY, Anene-Nzelu GC, Abdelhamid M, Adamopoulos S, Anker SD, Belenkov Y, Gal TB, Cohen-Solal A, Böhm M, Chioncel O, Jankowska EA, Gustafsson F, Hill L, Jaarsma T, Januzzi JL, Jhund P, Lopatin Y, Lund LH, Metra M, Milicic D, Moura B, Mueller C, Mullens W, Núñez J, Piepoli MF, Rakisheva A, Ristic A, Rossignol P, **Savarese G**, Tocchetti CG, van Linthout S, Volterrani M, Seferovic P, Rosano G, Coats AJ, Emdin M, Bayes-Genis A.

Cardiac Remodelling Part 2: Clinical, Imaging and Laboratory Findings A review from the Biomarkers Working Group of the Heart Failure Association of the ESC.

Eur J Heart Fail. 2022 Apr 30. doi: 10.1002/ejhf.2522. Online ahead of print. PMID: 35488811

2. González A, Richards AM, de Boer RA, Thum T, Arfsten H, Hülsmann M, Falcao-Pires I, Díez J, Foo RSY, Chan MY, Aimo A, Anene-Nzeliu CG, Abdelhamid M, Adamopoulos S, Anker SD, Belenkov Y, Gal TB, Cohen-Solal A, Böhm M, Chioncel O, Delgado V, Emdin M, Jankowska EA, Gustafsson F, Hill L, Jaarsma T, Januzzi JL, Jhund PS, Lopatin Y, Lund LH, Metra M, Milicic D, Moura B, Mueller C, Mullens W, Núñez J, Piepoli MF, Rakisheva A, Ristic AD, Rossignol P, **Savarese G**, Tocchetti CG, Van Linthout S, Volterrani M, Seferovic P, Rosano G, Coats AJS, Bayés-Genís A.

Cardiac remodelling - Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology.

Eur J Heart Fail. 2022 Mar 25. doi: 10.1002/ejhf.2493. Online ahead of print. PMID: 35334137

3. Mullens W, Coats A, Seferovic P, Metra M, Mebazaa A, Ruschitzka F, Filippatos G, Volterrani M, Ponikowski P, Jankowska EA, Chioncel O, McDonagh TA, Piepoli MF, Milicic D, Thum T, Hill L, Abdelhamid M, Adamopoulos S, Belenkov Y, Gal TB, Böhm M, Cohen-Solal A, Gustafsson F, Jaarsma T, Moura B, Rakisheva A, Ristic A, Bayes-Genis A, Van Linthout S, Anker SD, Tocchetti CG, Lopatin Y, Lund L, **Savarese G**, Čelutkienė J, Cowie M, Lambrinou E, Ray R, Lainscak M, Skouri H, Wallner M, Rosano GMC.

Education and certification on heart failure of the Heart Failure Association of the European Society of Cardiology.

Eur J Heart Fail. 2022;24:249-253. PMID: 35014132

4. Kapłon-Cieślicka A, Benson L, Chioncel O, Crespo-Leiro MG, Coats AJS, Anker SD, Filippatos G, Ruschitzka F, Hage C, Drożdż J, Seferovic P, Rosano GMC, Piepoli M, Mebazaa A, McDonagh T, Lainscak M, **Savarese G**, Ferrari R, Maggioni AP, Lund LH; on behalf of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) and the ESC Heart Failure Long-Term Registry Investigators.

A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction - insights from the ESC-HFA EORP Heart Failure Long-Term Registry.

Eur J Heart Fail. 2022;24:335-350. PMID: 34962044

5. Rosano G, Jankowska EA, Ray R, Metra M, Abdelhamid M, Adamopoulos S, Anker SD, Bayes-Genis A, Belenkov Y, Gal TB, Böhm M, Chioncel O, Cohen-Solal A, Farmakis D, Filippatos G, González A, Gustafsson F, Hill L, Jaarsma T, Jouhra F, Lainscak M, Lambrinou E, Lopatin Y, Lund LH, Milicic D, Moura B, Mullens W, Piepoli MF, Ponikowski P, Rakisheva A, Ristic A, **Savarese G**, Seferovic P, Senni M, Thum T, Tocchetti CG, Van Linthout S, Volterrani M, Coats AJS.

COVID-19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology.

Eur J Heart Fail. 2021;23:1806-1818. doi: 10.1002/ejhf.2356. PMID: 34612556

6. Rosano GMC, Moura B, Metra M, Böhm M, Bauersachs J, Ben Gal T, Adamopoulos S, Abdelhamid M, Bistola V, Čelutkienė J, Chioncel O, Farmakis D, Ferrari R, Filippatos G, Hill L, Jankowska EA, Jaarsma T, Jhund P, Lainscak M, Lopatin Y, Lund LH, Milicic D, Mullens W, Pinto F, Ponikowski P, **Savarese G**, Thum T, Volterrani M, Anker SD, Seferovic PM, Coats AJS.
Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology.
Eur J Heart Fail. 2021;23:872-881. PMID: 33932268
11. Seferović PM, Vardas P, Jankowska EA, Maggioni AP, Timmis A, Milinković I, Polovina M, Gale CP, Lund LH, Lopatin Y, Lainscak M, **Savarese G**, Huculeci R, Kazakiewicz D, Coats AJ; Developed in collaboration with the National Heart Failure Societies of the ESC member countries.
The Heart Failure Association Atlas: Heart Failure Epidemiology and Management Statistics 2019
Eur J Heart Fail. 2021;23:906-914. PMID: 33634931
12. Rossignol P, Lainscak M, Crespo-Leiro MG, Laroche C, Piepoli MF, Filippatos G, Rosano GMC, **Savarese G**, Anker SD, Seferovic PM, Ruschitzka F, Coats AJS, Mebazaa A, McDonagh T, Sahuquillo A, Penco M, Maggioni AP, Lund LH; Heart Failure Long-Term Registry Investigators Group.
Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry
Eur J Heart Fail. 2020;22:1378-1389. PMID: 32243669
13. Kapelios CJ, Lainscak M, **Savarese G**, Laroche C, Seferovic P, Ruschitzka F, Coats A, Anker SD, Crespo-Leiro MG, Filippatos G, Piepoli MF, Rosano G, Zanolta L, Aguiar C, Murin J, Leszek P, McDonagh T, Maggioni AP, Lund LH; Heart Failure Long-Term Registry Investigators.
Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world.
Eur J Heart Fail. 2019;21:1383-1397. PMID: 31132222
14. **Title Chapter: Liver and gut dysfunction**
Authors: Lopatin Y and Savarese G
Book Title: HFA textbook of Heart Failure (in press) – Textbook on heart failure produced by the Heart Failure Association of the European Society of Cardiology
Editors: Seferovic P, Coats AJ, Rosano G, Anker SD
Publisher: Oxford Medicine
15. **Title Chapter: Implantable Cardioverter Defibrillators**
Authors: Savarese G, Linde C and Dickstein K
Book Title: HFA textbook of Heart Failure (in press) – Textbook on heart failure produced by the Heart Failure Association of the European Society of Cardiology

Editors: Seferovic P, Coats AJ, Rosano G, Anker SD
Publisher: Oxford Medicine

16. Title Chapter: Clinical trial design and interpretation

Authors: Savarese G, Polovina M, Filippatos G, Vaduganathan M
Book Title: HFA textbook of Heart Failure (in press) – Textbook on heart failure produced by the Heart Failure Association of the European Society of Cardiology
Editors: Seferovic P, Coats AJ, Rosano G, Anker SD
Publisher: Oxford Medicine

- **European Society of Cardiology Working group on cardiovascular pharmacotherapy**

<https://www.escardio.org/Working-groups/Working-Group-on-Cardiovascular-Pharmacotherapy>

The Applicant is board member and has been secretary of the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology, which is the largest scientific society in the cardiovascular field worldwide.

The Working Group Nucleus Members carry on numerous scientific activities, in terms of publications, guidelines and teaching.

Heinz Drexel	Austria
Alexander Niessner	Austria
Basil Lewis	Israel
Sven Wassmann	Germany
Juan Luis Tamargo	Spain
Christian Tobias Torp-Pedersen	Denmark
Anne Grete Semb	Norway
Claudio Borghi	Italy
Keld Per Kjeldsen	Denmark
Iris Baumgartner	Switzerland
Stefan Agewall	Norway
Juan Carlos Kaski	UK
Giuseppe Rosano	UK
Claudio Ceconi	Italy
Elisabetta Cerbai	Italy
Dobromir Dobrev	Germany
Patrick Sulzgruber	Austria

1. Tamargo J, Kjeldsen KP, Delpón E, Semb AG, Cerbai E, Dobrev D, **Savarese G**, Sulzgruber P, Rosano G, Borghi C, Wassman S, Torp-Pedersen CT, Agewall S, Drexel H, Baumgartner I, Lewis BS, Ceconi C, Kaski JC, Niessner A. **Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy.** Eur Heart J Cardiovasc Pharmacother. 2022 Jan 29:pvac005. doi: 10.1093/ehjcvp/pvac005. Online ahead of print. PMID: 35092425

2. Magavern EF, Kaski JC, Turner RM, Drexel H, Janmohamed A, Scourfield A, Burrage D, Floyd CN, Adeyeye E, Tamargo J, Lewis BS, Kjeldsen KP, Niessner A, Wassmann S, Sulzgruber P, Borry P, Agewall S, Semb AG, Savarese G, Pirmohamed M, Caulfield MJ.
Challenges in cardiovascular pharmacogenomics implementation: a viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy.
Eur Heart J Cardiovasc Pharmacother. 2022;8:100-103. PMID: 34463331
3. Krogager ML, Kragholm K, Thomassen JQ, Sogaard P, Lewis BS, Wassmann S, Baumgartner I, Ceconi C, Schmidt TA, Kaski JC, Drexel H, Semb AG, Agewall S, Niessner A, **Savarese G**, Kjeldsen KP, Borghi C, Tamargo J, Torp-Pedersen C.
Update on management of hypokalaemia and goals for the lower potassium level in patients with cardiovascular disease: a review in collaboration with the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy.
Eur Heart J Cardiovasc Pharmacother. 2021;7:557-567. PMID: 33956964
4. Magavern EF, Kaski JC, Turner RM, Drexel H, Janmohamed A, Scourfield A, Burrage D, Floyd CN, Adeyeye E, Tamargo J, Lewis BS, Kjeldsen KP, Niessner A, Wassmann S, Sulzgruber P, Borry P, Agewall S, Semb AG, **Savarese G**, Pirmohamed M, Caulfield MJ.
The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy.
Eur Heart J Cardiovasc Pharmacother. 2022;8:85-99. PMID: 33638977
5. **Savarese G.**
All about clinical trial course: one of the masterpieces of the European Society of Cardiology-Working Group on Cardiovascular Pharmacotherapy educational programme.
Eur Heart J Cardiovasc Pharmacother. 2020;6:275-276. PMID: 32584980
6. **Savarese G**, Reiner MF, Uijl A, D Amario D, Agewall S, Atar D, Baumgartner I, Borghi C, De Carlo M, Drexel H, Kaski JC, Kjeldsen KP, Kucher N, Lund LH, Niessner A, Semb AG, Schmidt TA, Sulzgruber P, Tamargo J, Vitale C, Wassmann S, Aboyans V, Lewis BS.
Antithrombotic Therapy and Major Adverse Limb Events in Patients With Chronic Lower Extremity Arterial Disease: Systematic Review and Meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaboration with the European Society of Cardiology Working Group on Aorta & Peripheral Vascular Diseases.
Eur Heart J Cardiovasc Pharmacother 2020;6:86-93. PMID: 31392312
7. Sulzgruber P, Wassmann S, Semb AG, Doehner W, Widimsky P, Gremmel T, Kaski JC, **Savarese G**, Rosano GMC, Borghi C, Kjeldsen K, Torp-Pedersen C, Schmidt TA, Lewis BS, Drexel H, Tamargo J, Atar D, Agewall S, Niessner A.
Oral Anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1.

Eur Heart J 2019;40:3010-3012. PMID: 31541549

8. Hollan I, Ronda N, Dessein P, Agewall S, Karpouzas G, Tamargo J, Niessner A, **Savarese G**, Rosano G, Kaski JC, Wassmann S, Meroni PL.
Lipid management in rheumatoid arthritis: a position paper by the Cardiovascular Pharmacotherapy Working Group of European Society of Cardiology.
Eur Heart J Cardiovasc Pharmacother 2020;6:104-114. PMID: 31397840
9. Drexel H, Rosano GMC, Lewis BS, Huber K, Vonbank A, Dopheide JF, Mader A, Niessner A, **Savarese G**, Wassmann S, Agewall S.
The age of RCT's 3 Important Aspects of RCT's in Cardiovascular Pharmacotherapy with examples from Lipid and Diabetes Trials.
Eur Heart J Cardiovasc Pharmacother 2020;6:97-103. PMID: 31298686
10. Sulzgruber P, Wassmann S, Semb AG, Doehner W, Widimsky P, Gremmel T, Kaski JC, **Savarese G**, Rosano GMC, Borghi C, Kjeldsen K, Torp-Pedersen C, Schmidt TA, Lewis BS, Drexel H, Tamargo J, Atar D, Agewall S, Niessner A.
Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke.
Eur Heart J Cardiovasc Pharmacother 2019;5:171-180. PMID: 31119266
11. Vonbank A, Drexel H, Agewall S, Lewis BS, Dopheide JF, Kjeldsen K, Ceconi C, **Savarese G**, Rosano G, Wassmann S, Niessner A, Schmidt TA, Saely CH, Baumgartner I, Tamargo J.
Reasons for disparity in statin adherence rates between clinical trials and real-world observations: a review.
Eur Heart J Cardiovasc Pharmacother 2018;4:230-236. PMID: 30099530
12. Rosano GMC, Tamargo J, Kjeldsen KP, Lainscak M, Agewall S, Anker SD, Ceconi C, Coats AJS, Drexel H, Filippatos G, Kaski JC, Lund L, Niessner A, **Savarese G**, Schmidt TA, Seferovic P, Wassmann S, Walther T, Lewis BS.
Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with RAAS-inhibitors - Coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology.
Eur Heart J Cardiovasc Pharmacother 2018;4:180-188. PMID: 29726985
13. Niessner A, Tamargo J, Koller L, Saely CH, Schmidt TA, **Savarese G**, Wassmann S, Rosano G, Ceconi C, Torp-Pedersen C, Kaski JC, Kjeldsen KP, Agewall S, Walther T, Drexel H, Lewis BS.
Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy.
Eur Heart J 2018;39:2274-2281. PMID: 29126266
14. Tamargo J, Rosano G, Thomas W, Duarte J, Niessner A, Kaski JC, Ceconi C, Drexel H, Kjeldsen K, **Savarese G**, Torp-Pedersen C, Atar D, Lewis BS, Agewall S.